Case todayBrokenLate SEC filing · Nov 17, 2026The case · mixed · Nov 10, 2026Own BIXT if Bioxytran is a distressed clinical-stage option on galectin-antagonist antiviral data and oxygen-carrier science, with financing—not current operations—the gating variable.5 conditions1 strengthening · 2 holding · 2 weakeningNext resultsNot scheduledNo date filed yet

BIXT at a glance

The past year

Chart

−65.9% $0.02, close Nov 13

From the highest close
−74.4%
Vs the 200-day average
−24.6%
Nov 12, 2025Daily close, BioxytranNov 13, 2026

Short interest

History

3,141 shares

Since the last report
+100.0%
Days to cover
1.0 day
Settled
Sep 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 11 – Nov 17

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

BIXT price history

Latest price$0.02Today+$0.00 (+4.55%)
BIXT -7.95%S&P 500 -1.94%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • ProLectin-M only becomes an economic asset if Bioxytran converts its approved/cleared COVID IND path into a funded Phase 3 program rather than deferring trials for lack of capital.WeakeningMateriality: High

    MD&A states Bioxytran does not currently have sufficient capital resources and needs to raise approximately $3.7 million to fund about 15 months of development. If this holds, shareholders own a live pivotal-stage antiviral option; if it breaks, the lead program remains stranded science.

    Watch: Bioxytran fails to complete a public/private financing or strategic relationship before the planned Q3 2026 Phase 3 start window.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    MD&A states Bioxytran does not currently have sufficient capital resources and needs to raise approximately $3.7 million to fund about.

    Open source ↗
  • ProLectin-M must show that galectin antagonism creates a clinically meaningful acceleration of viral clearance, because natural Day 7 clearance across study arms would make the product hard to differentiate if Phase 3 confirms only a transient effect. needs calibration: pivotal.HoldingMateriality: High

    Item 1 describes a randomized, double-blind, placebo-controlled study in mild-to-moderate COVID-19 where PL-M patients showed higher Ct values by Day 3 and all treated subjects were above the cut-off by Day 7. Clinical differentiation is what turns a trial asset into partner interest, pricing power, and eventual commercialization value.

    Watch: A Phase 3 design or result fails to separate ProLectin-M from placebo on symptom improvement or viral-clearance timing that regulators view as clinically meaningful.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Item 1 describes a randomized, double-blind, placebo-controlled study in mild-to-moderate COVID-19 where PL-M patients showed higher Ct values by Day.

    Open source ↗
  • Common-shareholder value depends on whether Bioxytran can recapitalize on terms that fund trials without giving most of the future platform value to creditors or new investors.WeakeningMateriality: Medium

    FY2025 stockholders' equity was -$2,591,342, worse than -$1,791,949 at FY2024 year-end. Even good clinical data may not help current holders if survival financing is too dilutive or creditor-controlled.

    Watch: New convertible debt includes reset, variable-conversion, or deep-discount terms.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 stockholders' equity was -$2,591,342, worse than -$1,791,949 at FY2024 year-end.

    Open source ↗
  • Because Bioxytran cannot fund a broad platform, management must keep reallocating scarce spending away from promotion and overhead toward clinical and regulatory execution.StrengtheningMateriality: Medium

    FY2025 annual GAAP operating income was -$1,842,509, improved from -$2,223,068 in FY2024. Disciplined spending extends runway and increases the chance that each new share issued funds value-creating trial work rather than corporate drag.

    Watch: Management resumes material stock-promotion spending before trial funding is secured.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 annual GAAP operating income was -$1,842,509, improved from -$2,223,068 in FY2024.

    Open source ↗
  • BXT-25 is a real upside option only if the acellular oxygen carrier program moves from encouraging mouse safety into funded repeated-dose toxicity and IND-enabling work; otherwise it remains scientific optionality, not an economic engine.HoldingMateriality: Medium

    MD&A says BXT-25 was successfully tested in animals, with initial results showing non-toxicity and full recovery in Swiss Albino mice. If BXT-25 advances, Bioxytran has a second platform-like asset beyond COVID; if it stalls, valuation rests almost entirely on ProLectin-M.

    Watch: The planned rabbit and rat repeated-dose toxicity studies show toxicity or fail to support further development.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    MD&A says BXT-25 was successfully tested in animals, with initial results showing non-toxicity and full recovery in Swiss Albino mice.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

ProLectin-M only becomes an economic asset if Bioxytran converts its approved/cleared COVID IND path into a funded Phase 3 program rather than deferring trials for lack of capital. If this holds, shareholders own a live pivotal-stage antiviral option; if it breaks, the lead program remains stranded science.

ProLectin-M must show that galectin antagonism creates a clinically meaningful acceleration of viral clearance, because natural Day 7 clearance across study arms would make the product hard to differentiate if Phase 3 confirms only a transient effect. needs calibration: pivotal. Clinical differentiation is what turns a trial asset into partner interest, pricing power, and eventual commercialization value.

Common-shareholder value depends on whether Bioxytran can recapitalize on terms that fund trials without giving most of the future platform value to creditors or new investors. Even good clinical data may not help current holders if survival financing is too dilutive or creditor-controlled.

Because Bioxytran cannot fund a broad platform, management must keep reallocating scarce spending away from promotion and overhead toward clinical and regulatory execution. Disciplined spending extends runway and increases the chance that each new share issued funds value-creating trial work rather than corporate drag.

BXT-25 is a real upside option only if the acellular oxygen carrier program moves from encouraging mouse safety into funded repeated-dose toxicity and IND-enabling work; otherwise it remains scientific optionality, not an economic engine. If BXT-25 advances, Bioxytran has a second platform-like asset beyond COVID; if it stalls, valuation rests almost entirely on ProLectin-M.

All standing thesis claims
Original report summary

Bioxytran is a distressed clinical-stage option on galectin-antagonist antiviral data and oxygen-carrier science, with financing—not current operations—the gating variable.

Evidence assessed Nov 10, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Bioxytran

Where the evidence on Bioxytran disagrees: Mixed on the latest evidence (Nov 10, 2026). Of its 5 thesis points, 1 strengthening, 2 holding and 2 weakening.

Bull case: what the evidence supports

  • ProLectin-M must show that galectin antagonism creates a clinically meaningful acceleration of viral clearance, because natural Day 7 clearance across study arms would make the product hard to differentiate if Phase 3 confirms only a transient effect. needs calibration: pivotal.

    sec.gov ↗

  • Because Bioxytran cannot fund a broad platform, management must keep reallocating scarce spending away from promotion and overhead toward clinical and regulatory execution.

    sec.gov ↗

  • BXT-25 is a real upside option only if the acellular oxygen carrier program moves from encouraging mouse safety into funded repeated-dose toxicity and IND-enabling work; otherwise it remains scientific optionality, not an economic engine.

    sec.gov ↗

Bear case: what the evidence questions

  • ProLectin-M only becomes an economic asset if Bioxytran converts its approved/cleared COVID IND path into a funded Phase 3 program rather than deferring trials for lack of capital.

    sec.gov ↗

  • Common-shareholder value depends on whether Bioxytran can recapitalize on terms that fund trials without giving most of the future platform value to creditors or new investors.

    sec.gov ↗

Thesis-Break Engine

What has broken in Bioxytran’s thesis

Each break OptimistFi flagged on Bioxytran, dated — with what has historically followed the same kind of break across the market, not a forecast for Bioxytran.

peers+16%-43%-12%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -12% path vs comparable companies over six months, inside the middle-half range (+16% to -43%). A base rate, not a forecast.
  • Late SEC filingcondition set before this filing

    Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Other material event.

    Bioxytran filed an SEC 8-K on 2026-11-05: Other material event. It is a dated development that tests the current thesis.

  2. Mixed
    Other material event.

    Bioxytran filed an SEC 8-K on 2026-08-11: Other material event. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Bioxytran fails to complete a public/private financing or strategic relationship before the planned Q3 2026 Phase 3 start window.
  • A Phase 3 design or result fails to separate ProLectin-M from placebo on symptom improvement or viral-clearance timing that regulators view as clinically meaningful.
  • New convertible debt includes reset, variable-conversion, or deep-discount terms.
  • Management resumes material stock-promotion spending before trial funding is secured.
  • The planned rabbit and rat repeated-dose toxicity studies show toxicity or fail to support further development.

BIXT news

Loading headlines…

Financial statements

BIXT income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

BIXT: quick answers

What is BIXT's short interest?
As of September 30, 2026, 3,141 BIXT shares were sold short, up 100.0% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. BIXT short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.